258 related articles for article (PubMed ID: 37477768)
21. Comparison of Severe Acute Respiratory Syndrome Coronavirus 2 Spike Protein Binding to ACE2 Receptors from Human, Pets, Farm Animals, and Putative Intermediate Hosts.
Zhai X; Sun J; Yan Z; Zhang J; Zhao J; Zhao Z; Gao Q; He WT; Veit M; Su S
J Virol; 2020 Jul; 94(15):. PubMed ID: 32404529
[TBL] [Abstract][Full Text] [Related]
22. Competitive SARS-CoV-2 Serology Reveals Most Antibodies Targeting the Spike Receptor-Binding Domain Compete for ACE2 Binding.
Byrnes JR; Zhou XX; Lui I; Elledge SK; Glasgow JE; Lim SA; Loudermilk RP; Chiu CY; Wang TT; Wilson MR; Leung KK; Wells JA
mSphere; 2020 Sep; 5(5):. PubMed ID: 32938700
[TBL] [Abstract][Full Text] [Related]
23. The Cholesterol-Binding Sequence in Monomeric C-Reactive Protein Binds to the SARS-CoV-2 Spike Receptor-Binding Domain and Blocks Interaction With Angiotensin-Converting Enzyme 2.
Li HY; Gao N; Liu CY; Liu XL; Wu F; Dai N; Han J; Li QY
Front Immunol; 2022; 13():918731. PubMed ID: 35874670
[TBL] [Abstract][Full Text] [Related]
24. Enhanced Binding of SARS-CoV-2 Spike Protein to Receptor by Distal Polybasic Cleavage Sites.
Qiao B; Olvera de la Cruz M
ACS Nano; 2020 Aug; 14(8):10616-10623. PubMed ID: 32806067
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of S-protein RBD and hACE2 Interaction for Control of SARSCoV- 2 Infection (COVID-19).
Nayak SK
Mini Rev Med Chem; 2021; 21(6):689-703. PubMed ID: 33208074
[TBL] [Abstract][Full Text] [Related]
26. Probing structural basis for enhanced binding of SARS-CoV-2 P.1 variant spike protein with the human ACE2 receptor.
Lata S; Akif M
J Cell Biochem; 2022 Jul; 123(7):1207-1221. PubMed ID: 35620980
[TBL] [Abstract][Full Text] [Related]
27. Structural and simulation analysis of hotspot residues interactions of SARS-CoV 2 with human ACE2 receptor.
Veeramachaneni GK; Thunuguntla VBSC; Bobbillapati J; Bondili JS
J Biomol Struct Dyn; 2021 Jul; 39(11):4015-4025. PubMed ID: 32448098
[TBL] [Abstract][Full Text] [Related]
28. Biomechanical characterization of SARS-CoV-2 spike RBD and human ACE2 protein-protein interaction.
Cao W; Dong C; Kim S; Hou D; Tai W; Du L; Im W; Zhang XF
Biophys J; 2021 Mar; 120(6):1011-1019. PubMed ID: 33607086
[TBL] [Abstract][Full Text] [Related]
29. SARS-CoV-2 Spike Glycoprotein S1 Induces Neuroinflammation in BV-2 Microglia.
Olajide OA; Iwuanyanwu VU; Adegbola OD; Al-Hindawi AA
Mol Neurobiol; 2022 Jan; 59(1):445-458. PubMed ID: 34709564
[TBL] [Abstract][Full Text] [Related]
30. Critical Interactions Between the SARS-CoV-2 Spike Glycoprotein and the Human ACE2 Receptor.
Taka E; Yilmaz SZ; Golcuk M; Kilinc C; Aktas U; Yildiz A; Gur M
J Phys Chem B; 2021 Jun; 125(21):5537-5548. PubMed ID: 33979162
[TBL] [Abstract][Full Text] [Related]
31. An Active Site Inhibitor Induces Conformational Penalties for ACE2 Recognition by the Spike Protein of SARS-CoV-2.
Williams-Noonan BJ; Todorova N; Kulkarni K; Aguilar MI; Yarovsky I
J Phys Chem B; 2021 Mar; 125(10):2533-2550. PubMed ID: 33657325
[TBL] [Abstract][Full Text] [Related]
32. SARS-CoV-2 spike protein-mediated cell signaling in lung vascular cells.
Suzuki YJ; Nikolaienko SI; Dibrova VA; Dibrova YV; Vasylyk VM; Novikov MY; Shults NV; Gychka SG
Vascul Pharmacol; 2021 Apr; 137():106823. PubMed ID: 33232769
[TBL] [Abstract][Full Text] [Related]
33. Dual mechanism: Epigenetic inhibitor apabetalone reduces SARS-CoV-2 Delta and Omicron variant spike binding and attenuates SARS-CoV-2 RNA induced inflammation.
Fu L; Gilham D; Stotz SC; Sarsons CD; Rakai BD; Tsujikawa LM; Wasiak S; Johansson JO; Sweeney M; Wong NCW; Kulikowski E
Int Immunopharmacol; 2023 Apr; 117():109929. PubMed ID: 36857935
[TBL] [Abstract][Full Text] [Related]
34. Immunoglobulin yolk targeting spike 1, receptor binding domain of spike glycoprotein and nucleocapsid of SARS-CoV-2 blocking RBD-ACE2 binding interaction.
Eka Saputri M; Aisyah Rahmalia Effendi S; Nadila R; Azzam Fajar S; Damajanti Soejoedono R; Handharyani E; Nadia Poetri O
Int Immunopharmacol; 2022 Nov; 112():109280. PubMed ID: 36183680
[TBL] [Abstract][Full Text] [Related]
35. Structural Basis for Human Receptor Recognition by SARS-CoV-2 Omicron Variant BA.1.
Geng Q; Shi K; Ye G; Zhang W; Aihara H; Li F
J Virol; 2022 Apr; 96(8):e0024922. PubMed ID: 35343765
[TBL] [Abstract][Full Text] [Related]
36. Molecular basis for higher affinity of SARS-CoV-2 spike RBD for human ACE2 receptor.
Delgado JM; Duro N; Rogers DM; Tkatchenko A; Pandit SA; Varma S
Proteins; 2021 Sep; 89(9):1134-1144. PubMed ID: 33864655
[TBL] [Abstract][Full Text] [Related]
37. Potential therapeutic approaches for the early entry of SARS-CoV-2 by interrupting the interaction between the spike protein on SARS-CoV-2 and angiotensin-converting enzyme 2 (ACE2).
Xiang Y; Wang M; Chen H; Chen L
Biochem Pharmacol; 2021 Oct; 192():114724. PubMed ID: 34371003
[TBL] [Abstract][Full Text] [Related]
38. An angiotensin-converting enzyme-2-derived heptapeptide GK-7 for SARS-CoV-2 spike blockade.
Han S; Zhao G; Wei Z; Chen Y; Zhao J; He Y; He YJ; Gao J; Chen S; Du C; Wang T; Sun W; Huang Y; Wang C; Wang J
Peptides; 2021 Nov; 145():170638. PubMed ID: 34419496
[TBL] [Abstract][Full Text] [Related]
39. Identification of SARS-CoV-2 Receptor Binding Inhibitors by In Vitro Screening of Drug Libraries.
David AB; Diamant E; Dor E; Barnea A; Natan N; Levin L; Chapman S; Mimran LC; Epstein E; Zichel R; Torgeman A
Molecules; 2021 May; 26(11):. PubMed ID: 34072087
[TBL] [Abstract][Full Text] [Related]
40. Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding Domain.
Yang M; Li J; Huang Z; Li H; Wang Y; Wang X; Kang S; Huang X; Wu C; Liu T; Jia Z; Liang J; Yuan X; He S; Chen X; Zhou Z; Chen Q; Liu S; Li J; Zheng H; Liu X; Li K; Yao X; Lang B; Liu L; Liao HX; Chen S
Microbiol Spectr; 2021 Oct; 9(2):e0135221. PubMed ID: 34643438
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
